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Highlights


We present a case series of three patients with COVID-19 who had a cytokine panel which
revealed elevation of interleukin-6 (IL-6), but normal levels of interleukin-10 (IL-10),
interferon-gamma (INF-and interleukin-8 (IL-8) in contrast to the cytokine signature
1

described in Severe Acute Respiratory Syndrome (SARS) and Middle Eastern Respiratory
Syndrome (MERS).


We also documented evidence of a compromised T-cell IFN- response in two of these
patients.



Unlike other inflammatory conditions such as Acute Respiratory Distress Syndrome (ARDS),
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MERS and SARS, we saw no elevation of interleukin-1 beta (IL-1 suggesting that targeting
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of interleukin-1 (IL-1) pathway may not be of benefit in COVID-19.
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Research Letter
Abstract:
We present a case series of three patients with COVID-19 who had a cytokine panel which revealed
elevation of interleukin-6 (IL-6), but normal levels of interleukin-10 (IL-10), interferon-gamma (INFand interleukin-8 (IL-8) in contrast to the cytokine signature described in Severe Acute Respiratory
Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS). We also documented evidence

ro
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of a compromised T-cell IFN-gamma response in two of these patients.

Letter
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The clinical disease course of COVID-19, the disease caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), can progress to involve significant complications that may be

re

driven by a cytokine storm occurring during the second week of illness.(1, 2) Decompensation and

lP

increasing oxygen requirement during the second week is associated with elevated interleukin-6 (IL-6)
levels.(3) This cytokine storm appears to be different than that described for Severe Acute Respiratory

ur
na

Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS) in that there is elevated IL-6
rather than elevated levels of interferon-gamma (INF- and interleukin-13 (IL-13).(4) We present three
cases of individuals who had full cytokine profiles revealing elevated IL-6 and low IFN- levels and
evidence of compromised T-cell IFN- responses in contrast to the elevated levels of INF- and IL-13

Jo

levels described for SARS patients. The cytokine storm evident in COVID-19 that was observed in these
three patients was characterized by an elevation of interleukin-6 (IL-6), but normal levels of interleukin10 (IL-10), interferon-gamma (INF-and interleukin-8 (IL-8) and a compromised T-cell IFN- response
to mitogen challenge.
Three patients admitted to Northwell Plainview Hospital in Plainview, New York tested positive
for COVID-19 and had COVID-19 bilateral pneumonia with requirements for supplemental oxygen. The
3

patients progressed to severe respiratory failure. During what was assumed to be the cytokine storm
phase, based on laboratory parameters and a rising oxygen requirement, the patients received intravenous
steroids (methylprednisolone 1-2 mg/kg per day x 5-8 days) and the IL-6 receptor antagonist tocilizumab
400mg intravenously x1. All three patients had elevated levels of IL-6 but low levels of other cytokines
including IFN- and IL-13 (table 1). Two of these patients also underwent testing with an interferon
release assay to assess for latent tuberculosis and were observed to have a compromised T-cell IFN-

ro
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response as assessed by mitogen challenge (table 1).

Case 1: A 53-year-old male with no significant past medical history presented with 5 days of fever,

-p

malaise and difficulty breathing. On admission heart rate-96 beats per minute (bpm), respiratory rate-

on room air was 85%.

re

14 breaths per minute (BPM), temperature 39.30 C, blood pressure-122/51 mmHg and oxygen saturation
He was admitted and treated with methylprednisolone 1mg/kg intravenously
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daily but with increasing oxygen requirements an IL-6 level was drawn and the patient was treated with

ur
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tocilizumab 400mg intravenously x1. He improved and oxygen therapy was able to be de-escalated.

Case 2: A 50-year-old male with past medical history of hypertension, gastroesophageal disease, and
hyperlipidemia was admitted with fatigue and hypoxemia. On admission heart rate-114 bpm, respiratory
rate-18 BPM, temperature-380 C, blood pressure--122/78 mmHg and oxygen saturation on room air was
He was admitted and treated with methylprednisolone 1mg/kg intravenously daily but with

Jo

86%.

increasing oxygen requirements an IL-6 level was drawn and the patient was treated with tocilizumab
400mg intravenously x1. He did not improve and was intubated and placed on mechanical ventilation.
This individual had the lowest neutrophil lymphocyte ratio (NLR) of these individual so it is not clear
why this individual progressed to require mechanical ventilation. This individual did have the highest
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body mass index (BMI), the highest C-reactive protein (CRP), but only an intermediate level of IL-6 and
demonstrates even in this small series the variability of outcomes seen in COVID-19.

Case 3: A 45-year-old male with past medical history of asthma, gastroesophageal reflux, hyperlipidemia
and lumbago was brought in by ambulance with cough, fever, difficulty breathing and hypoxemia. On
admission heart rate-115 bpm, respiratory rate-22 BPM, temperature-38.80 C, blood pressure-124/86
He was admitted and treated with
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mmHg and oxygen saturation on room air was 88%.

methylprednisolone 1mg/kg intravenously daily but with increasing oxygen requirements an IL-6 level

ro

was drawn and the patient was treated with tocilizumab 400mg intravenously x1. He improved and
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oxygen therapy was able to be de-escalated. Pt was ultimately discharged on supplemental oxygen and

re

steroid taper.

The cytokine storm associated with SARS-CoV2 appears to be distinct from that seen in the
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patients infected with SARS and MERS as evidenced by elevated levels of IL-6 in the context of low
levels of IFN- and interleukin-8 (IL-8).(4, 5) Unlike other inflammatory conditions such as Acute
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Respiratory Distress Syndrome (ARDS), MERS and SARS, we saw no elevation of interleukin-1 beta
(IL-1 suggesting that targeting of interleukin-1 (IL-1) pathway may not be of benefit in COVID-19.(6)
This cytokine signature is consistent with other reports describing the dysregulation of the immune
response in patients with COVID-19 in Wuhan, China.

It is not clear from these observations which

Jo

cells are producing IL-6 as IL-6 may be produced by B-cells, T-cells, monocytes and even cells such as
fibroblasts not normally appreciated to be part of the immune response.(7) There does appear to be a
delay in the onset of the cytokine storm relative to onset of symptoms but it does not appear that this is
driven by ongoing antigenic stimulation due to viral replication based on prior studies of the viral
kinetics.(8) Studies of mild cases show clearing of infectious virus soon after the first week while studies
of hospitalized patients continue to have positive PCR tests well past the end resolution of symptoms.(9,
5

10) It is not clear if there is continued viral replication during the time of the described cytokine storm
and if interventions to address the hyperinflammatory state such as steroids or IL-6 receptor inhibition
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could lead to persistent viral replication.(11)
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Table 1: Patients with Cytokine Storm

Case (units) / (normal range)

1

2

3

53

50

45

27*

37*

33*

104

78

100

D-dimer (ng/mL) / (<229)

12377*

565*

10952*

Ferritin (ng/mL) / (15-150)

569*

655*

1309*

CRP (mg/dL) / (0.00-0.40)

1.54*

3.98*

1.69*

Age
Body mass index (kg/m2) / (18.5-24.9)
eGFR

(mL/min/1.73m2)

/ (>60)

of

Neutrophil lymphocyte ratio (NLR)/ (<3) 12.74/0.62=20.5* 3.93/0.35=11.2* 7.73/0.08=96.6*
Cytokine (units) / (normal range)

IL-2 (pg/mL) / (<2.1)

<5

IL-12 (pg/mL) / (<1.9)

<5

IFN-(pg/mL) / (<4.2)

<5

ro

<5

<5

<5

<5

<5

<5

-p

TNF- (pg/mL) / (<7.2)

<5

5

<5

<5

<5

<5

<5

<5

<5

18*

<5

6*

<5

<5

<5

<5

9*

<5

<5

<5

<5

42*

79*

114*

IL-8 (pg/mL) / (<3.0)

<5

<5

<5

Quantiferon TB Plus

Indeterminant*

-

Indeterminant*

Quantiferon TB Plus Nil
(IU/mL)

0.01

-

0.06

Quantiferon TB Plus TB1 minus Nil
(IU/mL)

0.00

-

0.01

Quantiferon TB Plus TB2 minus Nil
(IU/mL)

-0.01

-

0.00

Quantiferon TB Plus Mitogen minus Nil
(IU/mL)

0.04

-

0.03

IL-4 (pg/mL) / (<2.2)

re

IL-5 (pg/mL) / (<2.1)
IL-10 (pg/mL) / (<2.8)
IL-17 (pg/mL) / (<1.4)
IL-1-(pg/mL) / (<6.7)
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IL-6 (pg/mL) / (<2.0)

lP

IL-13 (pg/mL) / (<2.3)

*abnormal value
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